Novartis announced it has been recognized as one of the world’s most sustainable companies and named among Corporate Knights Global 100 2014. Corporate Knights revealed the final Global 100 Most Sustainable Corporations in the World at this year’s World Economic Forum in Davos.
Novartis CEO Joseph Jimenez said, “Our inclusion in the Global 100 list is a testimony to our longstanding commitment to corporate responsibility. Being recognized among the top 100 sustainability performers in the world underscores that doing business responsibly is a core part of Novartis.”
Corporate Knights narrowed an initial list of 4,000 publicly traded companies to 350 for the final evaluation. These were assessed using twelve key performance indicators (KPI) including energy productivity, employee turnover, and clean capitalism pay link, among others. Corporate Knight’s methodology aims to “unpackage ‘corporate sustainability’ into its component parts and stick to the numbers.”
Novartis said it intends to improve global health through its corporate actions. The company stated, “We collaborate with others to help address some of the world's greatest health challenges. To earn the trust of these collaborators and our customers, we need to do business responsibly, in a way that underscores our mission of caring and curing.” Novartis listed its priorities as working to control and eliminate diseases and searching for novel treatments to improve health in developing countries. The company also stated it works to pioneer innovative business approaches to establish connections with under-served patients. “We also care for our associates, strive to positively contribute to our communities, and protect the environment. We conduct business ethically, maintaining a Code of Conduct and governance system to ensure associates uphold our values.”
Novartis has also been listed in the STOXX Global ESG Leaders Index for the third year in a row and named among the 25 best multinational employers in the Great Place to Work list. Novartis has also been ranked top pharmaceutical corporation in Fortune’s World’s Most Admired Companies for the third consecutive year.